Bristol-Myers Squibb Company
CAMK2D antisense oligonucleotides and uses thereof
Last updated:
Abstract:
The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.
Status:
Grant
Type:
Utility
Filling date:
21 Feb 2019
Issue date:
13 Jul 2021